TFF Pharmaceuticals Inc

TFF Pharmaceuticals — Technical Presentation (December 2023)

42 slides from TFF Pharmaceuticals's technical presentation, Dec 19, 2023

  1. Slide 1: TFF VORI and TFF TAC: Presentation of Initial Phase 2 Data

    1 NASDAQ: TFFP BETTER DELIVERY, BETTER THERAPY | Powerful Drug Delivery Solutions TFF VORI and TFF TAC: Presentation of Initial Phase 2 Data December 19, 2023

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement SPECIAL NOTE REGARDING FORWARD - LOOKING STATEMENTS This document contains forward - looking statements concerning TFF Pharmaceuticals, Inc. (“TFF”, “TFF Pharmaceuticals”, the “Company,” “we,” “us,” and “our”). The words “believe,” “may,” “will,” “potentially,” “estimate,” “con

  3. Slide 3: Opening Remarks

    3 NASDAQ: TFFP BETTER DELIVERY, BETTER THERAPY | Powerful Drug Delivery Solutions Harlan Weisman, M.D., Chief Executive Officer Opening Remarks December 19, 2023

  4. Slide 4: TFF VORI Initial Data: Phase 2 and Expanded Access Program

    4 TFF VORI Initial Data: Phase 2 and Expanded Access Program

  5. Slide 5: TFF VORI: Addressing Significant Unmet Need in Pulmonary Fungal Infections

    1. Voriconazole Package Insert; Warning and Precautions section, 5.2 and 5.3 2. Maertens et. al. Lancet 2016; 387:760 - 769. 3. Bongomin et. al. Journal of Fungi. 2017 4. Internal estimates. Assumes indication for acute treatment of IPA TFF VORI: Addressing Significant Unmet Need in Pulmonary Fungal

  6. Slide 6: TFF VORI: Phase 2 Trial Design in Patients with Invasive Pulmonary Aspergillosis

    TFF VORI: Phase 2 Trial Design in Patients with Invasive Pulmonary Aspergillosis • Design : Open label randomized study; TFF VORI vs. oral voriconazole • Duration : 13 weeks of treatment • Endpoints : Safety/tolerability, clinical response, radiologic response, mycologic response, all - cause mortal

  7. Slide 7: TFF VORI: Expanded Access Program (EAP)

    • The Expanded Access Program (EAP) enrolls patients with the following diagnoses who have limited or no other treatment options or who have had an unfavorable response to adequate standard of care therapy: Pulmonary aspergillosis: ▪ Invasive pulmonary aspergillosis (IPA) ▪ Chronic pulmonary aspergi

  8. Slide 8: TFF VORI: Initial Data Readout

    Based on the highly encouraging results of the initial data readout , we plan to accelerate the development of TFF VORI into registration - enabling studies. The data readout includes: • Assessment of efficacy: Clinical response ▪ Improved signs and symptoms (heatmap with red representing more signs

  9. Slide 9: TFF VORI: Summary of Results

    Efficacy • Of the five patients treated for at least 8 weeks with TFF VORI: • All five patients achieved a clinical response (improvement in signs, symptoms and/or spirometry) • All five patients achieved a mycologic response (presumed or proven ) • Three of four patients achieved a radiologic respo

  10. Slide 10: TFF VORI: Baseline Characteristics and Demographics

    EAP: expanded access program; CLAD: chronic lung allograft dysfunction Data is from pre - database lock; Data cut off date: 11/17/23 TFF VORI: Baseline Characteristics and Demographics C o mpl e t ed t r e a tment? Last visit in the t r e a tment p eri o d CLAD Ho st f ac t o r Race Sex Age ( y e a

  11. Slide 11: TFF VORI: Efficacy Assessment

    Patients who completed at least 8 weeks of treatment TFF VORI: Efficacy Assessment 11 A ll - c a use m o r t a li t y C o mpl e t ed treatment CLAD R a d i o l o gi c response M y co l o gic response Clinical response T r e a tment duration Patient Im p r o v e d C T findings No evidence of infectio

  12. Slide 12: TFF VORI: Patient Oral 1 (Phase 2)

    12 T o tal S ym p t o m S co r es Week 17 Week 13 Week 8 Week 4 Week 2 Week 1 D a y 1 Screening 1 0 6 5 5 6 2 2 Oral 1 All - cause mortality R a d i o l o gi c response Mycologic response Clinical response T r e a tment duration Patient Im p r o v e d C T findings No evidence of infection Stable or

  13. Slide 13: TFF VORI: Patient Oral 1 (Phase 2) imaging

    13 B a se li ne Week 13 Bronchial wall thickening/ obstruction with air trapping TFF VORI: Patient Oral 1 (Phase 2) Data is from pre - database lock; Data cut off date: 11/17/23

  14. Slide 14: TFF VORI: Patient TFF VORI 1 (Phase 2)

    Data is from pre - database lock; Data cut off date: 11/17/23 14 T o tal s ym p t o m sco r e Week 13 Week 8 Week 4 Week 1 D a y 1 Screening 3 9 8 6 6 8 T FF V ORI 1 All - cause mortality R a d i o l o gi c response Mycologic response Clinical response T r e a tment duration Patient Im p r o v e d C

  15. Slide 15: TFF VORI: Patient TFF VORI 1 imaging

    B a se li ne Week 13 TFF VORI: Patient TFF VORI 1 (Phase 2) 15 Data is from pre - database lock; Data cut off date: 11/17/23 Aspergillus Nodules

  16. Slide 16: TFF VORI: Patient TFF VORI 2 (Phase 2)

    All - cause mortality R a d i o l o gi c response Mycologic response Clinical response T r e a tment duration Patient Im p r o v e d C T findings No evidence of infection Stable or improved spirometry Im p r o v e d s igns and symptoms No x x x pending 8+ weeks T F F V ORI 2 T o t a l S y m pt o m S

  17. Slide 17: TFF VORI: Patient TFF VORI 2 imaging

    B a se li ne Week 8 TFF VORI: Patient TFF VORI 2 (Phase 2) 17 Data is from pre - database lock; Data cut off date: 11/17/23

  18. Slide 18: TFF VORI: Patient TFF VORI 4 (EAP)

    18 All - cause mortality R a d i o l o gi c response Mycologic response Clinical response T r e a tment duration Patient Im p r o v e d C T findings No evidence of infection Stable or improved spirometry Im p r o v e d s igns and symptoms No x x x x 24 weeks T F F V ORI 4 T o t a l S y m pt o m S co

  19. Slide 19: TFF VORI: Patient TFF VORI 4 imaging

    19 B a se li ne ~Week 12 TFF VORI: Patient TFF VORI 4 (EAP) Data is from pre - database lock; Data cut off date: 11/17/23

  20. Slide 20: TFF VORI: Patient TFF VORI 5 (EAP)

    TFF VORI: Patient TFF VORI 5 (EAP) 54 - yr - old white female lung transplant recipient and CLAD presented with moderate cough and dyspnea (shortness of breath) and BAL evidence of Aspergillus 20 All - cause mortality R a d i o l o gi c response Mycologic response Clinical response T r e a tment dur

  21. Slide 21: TFF VORI: Patient TFF VORI 6 (EAP)

    TFF VORI: Patient TFF VORI 6 (EAP) 59 - yr - old white female lung transplant recipient presented with mild cough and dyspnea (shortness of breath) and BAL evidence of Aspergillus All - cause mortality R a d i o l o gi c response Mycologic response Clinical response T r e a tment duration Patient Im

  22. Slide 22: TFF VORI: Clinical Signs and Symptoms

    Patients who completed at least 8 weeks of treatment 22 Data is from pre - database lock; Data cut off date: 11/17/23 TFF VORI: Clinical Signs and Symptoms End of Treatment Screening 0 2 Oral 1 3 8 TFF VOR 1 pending 1 TFF VORI 2 3 6 TFF VORI 4 2 4 TFF VORI 5 1 2 TFF VORI 6 Total Symptom Score

  23. Slide 23: Spirometry

    Open circles indicate imputed numbers. 23 Data is from pre - database lock; Data cut off date: 11/17/23 0 20 40 60 80 1 0 0 Pr e S c r S c r een Da y 1 W k 1 W k 2 W k 4 W k 6 /8 W k 1 2 / 1 3 W k 1 7 / 24 FE V - 1 % Oral 1 T F F V O R I 1 T F F V O R I 2 T F F V O R I 4 T F F V O R I 5 T F F V O R

  24. Slide 24: TFF VORI: Mycological Assessment

    Post - treatment mycologic evaluation (galactomannan/PCR) Baseline mycologic evidence (culture, microscopy and/or galactomannan) Patient Serum galactomannan & blood PCR Negative BAL positive Oral 1 Serum galactomannan & blood PCR Negative BAL positive T F F V ORI 1 Serum galactomannan & blood PCR Ne

  25. Slide 25: TFF VORI: Radiologic Assessment

    Post - treatment radiologic evaluation Baseline radiologic evidence Patient Resolved Bronchial wall thickening Oral 1 Resolved Nodules and bronchial wall thickening T F F V ORI 1 Resolved Nodules T F F V ORI 2 Resolved Nodules T F F V ORI 4 Not resolved Single pre - existing nodule T F F V ORI 5 Che

  26. Slide 26: TFF VORI: Efficacy Assessment

    Patients who completed at least 8 weeks of treatment TFF VORI: Efficacy Assessment A ll - c a use m o r t a li t y C o mpl e t ed treatment CLAD R a d i o l o gi c response M y co l o gic response Clinical response T r e a tment duration Patient Im p r o v e d C T findings No evidence of infection S

  27. Slide 27: TFF VORI: Safety Data

    TFF V O R I ( n = 7) O ral ( n = 2) 14 13 Number of TEAEs 2 (29%) 2 (100%) Number of patients with any TEAEs 0 0 Number of related TEAEs 5 8 Number of possibly or probably related TEAEs 2 (29%) 1 (50%) Number of patients with possibly or probably related TEAEs 3 2 Number of Grade 3 and above TEAEs 1

  28. Slide 28: TFF TAC Phase 2 Initial Results

    TFF TAC Phase 2 Initial Results 28

  29. Slide 29: TFF TAC: Phase 2 development for prevention of rejection in lung transplant

    Increase lung delivery to drive efficacy while minimizing systemic exposures, toxicities, and drug - drug interactions 29 TFF TAC is in Phase 2 development for prevention of rejection in lung transplant recipients • Tacrolimus is first - line calcineurin inhibitor for prevention of rejection in lung

  30. Slide 30: TFF TAC: Phase 2 Trial Design in Lung Transplant Patients

    TFF TAC: Phase 2 Trial Design in Lung Transplant Patients • Design : Open label study of TFF TAC in lung transplant patients who require reduced tacrolimus blood levels due to kidney toxicity • Duration : Part A: 12 weeks; Part B: optional safety extension • Endpoints : Safety and tolerability, kidn

  31. Slide 31: TFF TAC: Initial Data Readout

    TFF TAC: Initial Data Readout Definition of success: Transition patients from oral tacrolimus to TFF TAC, achieve tacrolimus blood levels that are approximately two - thirds to one - half of the patient's blood levels on oral tacrolimus, prevent rejection at these diminished tacrolimus blood levels

  32. Slide 32: TFF TAC: Summary of Results

    32 Efficacy • Successful transition of 4/4 patients from oral Tacrolimus to TFF TAC • Successful lowering of Tacrolimus blood levels No clinical evidence of acute rejection No signs and symptoms suggestive of acute rejection No use of pulse corticosteroids No deterioration in spirometry No chest x -

  33. Slide 33: TFF TAC: Baseline Characteristics and Demographics

    TFF TAC: Baseline Characteristics and Demographics Disposition Last visit in the t r e a tment p eri o d Y e a rs w ith k i d n e y d ise a se CLAD Y e a rs sin c e transplant Race Sex Age Patient Chose to proceed to Part B Week 26 5 No 9 W M 73 Pt 1 Chose to proceed to Part B Day 86 6 No 8 W F 73 P

  34. Slide 34: TFF TAC: Oral Tacrolimus to TFF TAC Dose Translation

    Tacrolimus blood levels on T FF T A C ( ng / ml) S t a b le T FF T A C d o se Tacrolimus blood levels on oral Tacrolimus (ng/ml) Stable oral T ac r o limus d o se Patient 2.4 ~1/2 of oral level 0.75 mg ~1/7 of oral dose 5.6 5 mg Pt 1 2.6 2/3 of oral level 0.25 mg 1/4 of oral dose 3.9 1 mg Pt 2 2.2 ~

  35. Slide 35: Spirometry Data

    Spirometry Data 35 Data is from pre - database lock; Data cut off date: 11/29/23

  36. Slide 36: Kidney Function: Creatinine and GFR

    Kidney Function: Creatinine and GFR 10 0 20 30 40 60 50 - 2 4 W k s - 1 2 W k s S c ree n i n g D a y 1 D a y 8 D a y 15 D a y 22 D a y 29 D a y 57 D a y 85 Wk 26 e G F R Pt 1 Pt 2 Pt 3 Pt 4 50 0 100 150 250 200 - 24 Wks - 12 Wks Screening D a y 1 D a y 8 D a y 15 D a y 22 D a y 29 D a y 57 D a y 85

  37. Slide 37: TFF TAC: Safety Data

    37 TFF T A C ( n = 4) 14 Number of TEAEs 4 (100%) Number of patients with any TEAEs 0 Number of related TEAEs 9 Number of probably or possibly related TEAEs 2 (50%) Number of patients with possibly or probably related TEAEs 2 Number of Grade 3 and above TEAEs 1 (25%) Number of patients with Grade 3

  38. Slide 38: Thank You

    38 NASDAQ: TFFP BETTER DELIVERY, BETTER THERAPY | Powerful Drug Delivery Solutions THANK YOU

  39. Slide 39: TFF VORI: Patient TFF VORI 1 (Phase 2)

    B a se li ne D a y 5 6 D a y 9 1 TFF VORI: Patient TFF VORI 1 (Phase 2) 39 Data is from pre - database lock; Data cut off date: 11/17/23 Ground glass opacities unrelated SAE N od u l e s

  40. Slide 40: TFF VORI: Patient TFF VORI 1 (Phase 2)

    B a se li ne D a y 5 6 D a y 9 1 TFF VORI: Patient TFF VORI 1 (Phase 2) 40 Data is from pre - database lock; Data cut off date: 11/17/23 Ground glass opacities unrelated SAE N od u l e s

  41. Slide 41: TFF VORI: Patient imaging

    B a se li ne D a y 5 6 TFF VORI: Patient TFF VORI 2 (Phase 2) 41 Data is from pre - database lock; Data cut off date: 11/17/23

  42. Slide 42: TFF VORI: Clinical Signs and Symptoms

    Total Symptom Scores 1 0 6 5 5 6 2 2 Oral 1 3 9 8 6 6 8 TFF VORI 1 1 1 1 1 1 1 TFF VORI 2 3 6 TFF VORI 4 2 4 TFF VORI 5 1 1 2 TFF VORI 6 Patients who completed at least 8 weeks of treatment TFF VORI: Clinical Signs and Symptoms • Far - left column represents signs and symptoms at screening • Far - r

TFF Pharmaceuticals — Technical Presentation (December 2023) on 6ix